Physician profile
Erin Beasley
NPI 1679103808
$1,261.45
in general payments reported to CMS, 2019-2025
19 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $178 · 2023: $351 · 2024: $277 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842 · Consulting Fee: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.93 |
| Consulting Fee | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $248.12 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.05 | 2022-2025 | Hyqvia, Cuvitru |
| Biogen, INC. | $120.00 | 2023-2025 | Tysabri |
| Abbvie INC. | $117.76 | 2021-2024 | |
| Csl Behring | $99.40 | 2022-2025 | Hizentra |
| Kedrion Biopharma, INC. | $80.00 | 2023 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Melinta Therapeutics, LLC | $62.46 | 2024 | Kimyrsa, Rezzayo, Orbactiv |
| Lundbeck LLC | $62.00 | 2023-2024 | Vyepti |
| Argenx US, INC. | $42.80 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $37.55 | 2021-2022 | |
| Lilly USA, LLC | $35.53 | 2022-2024 | Kisunla |
| Genzyme Corporation | $26.41 | 2024 | |
| Sanofi-Aventis U.S. LLC | $26.21 | 2021-2022 | |
| Janssen Biotech, INC. | $23.52 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $18.83 | 2024 | Tezspire |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.54 | 2021 | |
| Grifols USA, LLC | $17.61 | 2025 | Gamunex-C |
| Novartis Pharmaceuticals Corporation | $14.78 | 2022 | |
| Glaxosmithkline, LLC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Beasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.